(Reuters) - Allergan Plc is considering options for its women’s health unit, including a sale, Bloomberg reported on Monday, citing people with knowledge of the matter.
A sale, which would likely attract interest from private equity firms, could value the business at more than $5 billion, according to the Bloomberg report.
The women’s health unit, which makes oral contraceptive pills to menopause treatment, raked in $1.04 billion sales in 2017.
A decision on whether to pursue a sale hasn’t been made and the Botox maker could choose to keep the business, Bloomberg reported. An Allergan spokeswoman declined to comment.
The company’s shares closed at $162.27, and have fallen about 34 percent in the last twelve months.
Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Shounak Dasgupta
Our Standards: The Thomson Reuters Trust Principles.